about
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology.Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationDendritic-cell-based therapeutic cancer vaccinesLarge-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging.Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Designing the optimal vaccine: the importance of cytokines and dendritic cells.Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cellsPersonalized dendritic cell-based tumor immunotherapy.Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer.Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells.Dendritic cell preparation for immunotherapeutic interventions.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Generation of immunogenic and tolerogenic clinical-grade dendritic cells.T cells as vehicles for cancer vaccinationDendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.Rationale for stimulator of interferon genes-targeted cancer immunotherapy.Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery.Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients.Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.Tumour regression induced by co-administration of MIP-3α and CpG in an experimental model of colon carcinoma.In vivo cellular MRI of dendritic cell migration using micrometer-sized iron oxide (MPIO) particles.A large-scale 19F MRI-based cell migration assay to optimize cell therapy
P2860
Q26830857-5BF3CAC3-DFB8-4416-BAE1-FB1A1351EE3FQ33690978-08D179EC-3CAF-4EB7-BF20-D41989BFEC9DQ33994982-14E33ACC-802D-41F3-BDB1-1BDC1302BE32Q34068404-6E9B17E5-A459-4A45-A891-CA1E2BBB3B23Q34360094-7A053128-90FF-4E3C-92DE-EBCE6DD0381CQ34372167-BB5DAC37-3E69-4C11-9B13-38FD109600CAQ34892779-E4F625F2-6567-4866-B3FF-4E5F07A10A3AQ34898366-6E43FCB7-4AFD-4B39-8086-E39C54B25370Q35146556-C7AC9E86-A1C6-4A20-B049-6E093396B973Q36168088-E76BAB72-469E-46C9-9366-8FCD9D53A2DCQ36759294-ECBD5CBD-139C-4383-8F24-836D2AAC2579Q37017101-E6AE1080-5471-4099-9FA5-C621F333C6CEQ37668941-693505FE-D007-4F44-935D-1D5CFE154D15Q37693733-C48260E1-92F7-413D-B597-019FFFE08F7EQ37698608-4B4A472E-9E64-4E11-BF1C-18D3B05E2534Q37729202-C154D05D-D62C-4309-BA35-01EFD9406062Q37773266-A2949BF8-DA5D-455A-8B72-1E8A53205414Q37801939-E0AF2774-D826-43EC-A532-891594B77151Q37959362-D4189016-4504-40F0-B349-A44C5C568A35Q37963343-8A36139D-D3E2-48B6-A6A8-D846792FAC70Q38059516-EA11DCD4-1F24-4C1E-B7C3-539E11F407C3Q38261273-45581BDD-4483-47A7-9C13-0DE2D6419623Q39144454-6A6A21E6-3298-4FB5-A103-7E9058E1275BQ39631867-C1ECFD97-DE98-4F59-AEAD-14600843D3ECQ40278871-FE772A0B-969D-46EE-A0B2-0B71CC19BFD6Q40365927-5EEF30F8-C58A-44E1-9346-59BD2D1F13B6Q41205250-4DDAF57B-D042-4BC7-ADAC-B8B7421C8F01Q41867724-98ABF976-57A0-4CE4-A61B-0059F6EDAE42Q41976096-F1F55872-D5CA-4C49-B97E-15188BB18485Q44828889-D108F30A-BBE8-4BF2-8822-B6B68384577DQ50542287-3ECDC4F7-B4FF-4B16-8C0C-F2FA00AF6293Q58619881-C1C7BEC9-9535-40DD-818E-9D2EDC1EA6C6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dendritic cell vaccination and immune monitoring.
@en
Dendritic cell vaccination and immune monitoring.
@nl
type
label
Dendritic cell vaccination and immune monitoring.
@en
Dendritic cell vaccination and immune monitoring.
@nl
prefLabel
Dendritic cell vaccination and immune monitoring.
@en
Dendritic cell vaccination and immune monitoring.
@nl
P2093
P2860
P921
P1476
Dendritic cell vaccination and immune monitoring
@en
P2093
C J A Punt
E H J G Aarntzen
I J M de Vries
P2860
P2888
P304
P356
10.1007/S00262-008-0553-Y
P50
P577
2008-07-10T00:00:00Z